Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
GLAXO Stock Chart & Stats
₹2483.35
-₹2.55(-0.12%)
At close: 4:00 PM EST
₹2483.35
-₹2.55(-0.12%)
Day’s Range― - ―
52-Week Range₹2,220.00 - ₹3,515.95
Previous CloseN/A
Volume25.42K
Average Volume (3M)1.83K
Market Cap
₹412.27B
Enterprise Value₹404.47B
Total Cash (Recent Filing)₹20.61B
Total Debt (Recent Filing)₹357.10M
Price to Earnings (P/E)35.4
Beta0.73
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.16%
Share Statistics
EPS (TTM)16.70
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)24.29
Price to Sales (P/S)12.64
P/FCF Ratio37.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)61.38
Revenue Forecast (FY)₹38.91B
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthExtremely low leverage (D/E 0.005) and substantial liquidity provide durable financial flexibility for R&D, manufacturing and tender participation. High ROE indicates efficient capital use, reducing refinancing risk and supporting long-term investment capacity over the next 2–6 months.
Robust Cash GenerationVery strong FCF growth and OCF/Net Income above 1 show the business converts earnings to cash reliably. This sustainable cash generation supports product investment, dividend funding and balance-sheet resilience against regulatory or pricing headwinds over the medium term.
High Margins And ProfitabilityElevated gross and net margins with strong EBIT/EBITDA indicate structural cost advantages or pricing power in core products. Combined with consistent revenue growth, margins provide durable cash flow protection and reinvestment capacity, supporting sustainable returns over coming quarters.
Bears Say
Recent Revenue Growth SlowdownA modest short-term revenue growth figure (~2.6%) versus higher annual growth signals potential recent softening in demand or timing differences in tender cycles. Slower near-term top-line momentum can constrain incremental R&D or marketing spend and pressurize medium-term growth expectations.
Limited Investor Disclosure / GuidanceAbsence of earnings call data and formal guidance reduces transparency and makes forecasting near-term revenues, margin trajectory and capital allocation harder for investors. This limits visibility into management priorities and could complicate external assessment over the next few reporting cycles.
Low Trading LiquidityVery low average trading volume suggests limited market liquidity, which can restrict institutional participation, widen transaction costs and make sizable position adjustments difficult without market impact. This structural liquidity constraint can affect investor appetite and secondary market flexibility.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2220.00 and its highest was ₹3515.95 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹412.27B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is May 19, 2026 which is in 62 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on Feb 09, 2026. The company reported ₹16.7 earnings per share for the quarter, the consensus estimate of ₹16.7 by ₹0.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹42 which represents an annual dividend yield of 2.16%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹16.7 in its last earnings report, expectations of ₹16.7. Following the earnings report the stock price went up 1.012%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―